Multiple Sclerosis and Cannabinoids: An Evidence-Based Approach

By Fernando Caudevilla (DoctorX)

The immune system, often mistakenly conceived as a simple defensive barrier against external invaders, performs vital and complex functions within the body. Its ability to distinguish between “self” and “non-self” is fundamental; however, when it fails in this critical distinction, devastating autoimmune diseases are triggered. Multiple Sclerosis (MS) represents one of the most tragic examples of this failure: the immune system attacks myelin, the protective layer that covers neurons in the brain and spinal cord. This demyelinating attack disrupts nerve transmission, causing a cascade of symptoms that can drastically alter patients’ quality of life.

In the current therapeutic landscape, where there is no definitive cure for this neurological condition, research has focused its attention on how to modulate symptoms. Among the emerging strategies is the use of cannabinoids. This article rigorously examines the available scientific evidence regarding their clinical utility, differentiating between regulated drugs and alternative uses, always from a perspective of harm reduction and medical prudence.

Pathophysiology and the role of cannabinoids

To understand the therapeutic intervention, it is necessary to visualize neuronal anatomy. Neurons act as transmission cables; their axon is covered by myelin, analogous to the insulating plastic that protects an electrical wire. In MS, the immune system attacks this insulation, causing neurological short circuits that manifest clinically.

The cannabis plant contains chemical compounds known as cannabinoids, which interact with specific receptors in our body: CB1 and CB2. CB1 receptors are abundant in the Central Nervous System and regulate motor functions, posture, and pain perception. Preclinical studies indicate that these receptors play a crucial role in modulating muscle stiffness.

For their part, CB2 receptors are expressed mainly in glial cells (such as microglia) and are involved in the inflammatory response. Tetrahydrocannabinol (THC), the main psychoactive component, strongly activates these receptors, while cannabidiol (CBD) does not produce significant psychotropic effects but does enhance clinical benefits without altering consciousness.

The drug Sativex: Evidence and regulation

The combination of THC and CBD in an equal (1:1) ratio is currently considered the therapeutic standard for this indication. This formulation allows for maximizing the anti-spastic effect while minimizing the psychotropic adverse effects of THC.

There is a marketed medication, Sativex, administered transmucosally (sublingual spray). This drug contains cloned cannabis extract with a precise dosage: 27 mg/ml of THC and 25 mg/ml of CBD. After controlled clinical trials demonstrated its efficacy in patients with moderate or severe spasticity refractory to other treatments, the Spanish Agency for Medicines and Health Products approved its use in July 2010.

It is essential to understand the regulatory context: Sativex is classified as a second-line treatment. Its prescription is reserved for patients who have not obtained an adequate response with conventional anti-spastic drugs. Clinical trials revealed that approximately 40% to 50% of participants discontinued the medication after a few weeks, either due to perceived lack of efficacy or significant adverse effects.

In those patients who tolerate the treatment well, clinical improvement is observed in three critical areas: muscle stiffness (spasticity), neuropathic pain, and urinary symptoms. However, it is crucial to distinguish between symptomatic relief and disease modification. Specific studies have not found solid evidence that cannabinoids halt the progression of demyelination or reduce the frequency of relapses.

Economic limitations and access

Despite its demonstrated efficacy, access to this treatment faces significant barriers. The monthly cost ranges between 400 and 600 euros, depending on the daily administration regimen required by each patient. Furthermore, for the National Health System to cover the expenses, it is necessary to process a medical-administrative inspection permit, a complex bureaucratic process that often delays or prevents timely access.

Like any drug, Sativex has contraindications and side effects. The symptomatic nature of the treatment means that it does not stop the underlying disease; it simply helps the patient manage their daily symptoms with a better quality of life.

Smoked cannabis and artisanal extracts: Sufficient evidence?

A recurring question in the field of therapeutic cannabis is whether alternative methods, such as smoking the plant or using homemade tinctures, offer similar benefits. Regarding smoked consumption, there is one clinical trial that suggests positive effects on pain and spasticity compared to a placebo.

However, this study has significant methodological limitations: it was conducted on a small sample of 37 patients for only three days under controlled experimental conditions. The study authors explicitly warn that larger-scale studies with variable doses are needed to confirm these findings. It is unlikely that the pharmaceutical industry or regulatory agencies will fund new trials with smoked cannabis, given the legal status of the substance in many countries.

As for artisanal extracts (oils or tinctures), their production is economically viable and accessible. However, as with smoked consumption, the lack of public funding to conduct rigorous clinical trials prevents the scientific validation of their efficacy and safety compared to the marketed drug.

Harm reduction and editorial conclusion

Although approximately 13% to 40% of patients diagnosed with MS use cannabis derivatives to manage their symptoms, clinical reality demands prudence. Current scientific evidence mainly supports the use of standardized products like Sativex in a strict medical context.

From Psiconáutica.org, we advocate for medical care that transcends social prejudices and taboos, ensuring that no patient is left unattended. However, the absence of regulation is not equivalent to a guarantee of standardized safety or efficacy. The variability in the composition of plants grown outside of industrial control introduces uncertainty regarding exact dosage and purity.

The therapeutic decision must be shared between the patient, their specialized neurologist, and, where appropriate, a clinical pharmacist. Prioritizing regulated references for oral or transmucosal administration is a fundamental harm reduction measure. Cannabis can be a valuable tool in the therapeutic arsenal against MS, but it must be integrated with scientific rigor, avoiding unrealistic expectations about miracle cures and maintaining a sober approach focused on the real improvement of physical and mental well-being.